Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2025.110253 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Steffi Hartmann und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Hospital Rostock, Rostock, Germany. Electronic address: steffi.hartmann@kliniksued-rostock.de. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Fiducial Markers, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merit Medical Systems.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Marking metastatic lymph nodes before neoadjuvant chemotherapy (NACT) has become increasingly popular in the surgical treatment of breast cancer. A variety of devices are currently in use. However, the significance of lost markers is poorly understood, and their impact on clinical decisions is unclear. MATERIALS AND METHODS: Among participants enrolled in the prospective AXSANA cohort study, those planned for target lymph node biopsy (TLNB) or targeted axillary dissection (TAD) with completed post-NACT locoregional therapy (surgery and radiotherapy) by January 21, 2025, were included. RESULTS: In 88 of 1528 patients (5.8 %), axillary markers could not successfully be removed during surgery after NACT. The lost marker rate differed depending on the marker type (metallic clip/coil 7.0 %, carbon 3.1 %, radar reflector 1.4 %, magnetic seed 0.6 %, radioactive seed 0.0 %, p < 0.001). Additional postoperative imaging was performed in 25 (28.4 %) and further surgery to remove axillary markers was performed in 6 (6.8 %) patients with lost markers. The proportion of patients undergoing axillary lymph node dissection (46.6 % versus 36.5 %, p 0.069) and axillary radiotherapy (51.1 % versus 50.2 %, p 0.748) did not differ between patients with and without lost markers. After an average follow-up of 21.8 months, axillary recurrences occurred in 3 patients (3.3 %) with and 16 patients (1.0 %) without lost markers (rate ratio 2.89, p 0.088). CONCLUSION: The loss of markers in TLNB/TAD is uncommon and significantly depends on the marking technique. Lost markers may lead to diagnostic uncertainties and additional imaging or surgical procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, University Hospital Rostock, Rostock, Germany. Electronic address: steffi.hartmann@kliniksued-rostock.de.
- Department of Obstetrics and Gynecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Gynecology and Obstetrics, Müritz-Klinikum Waren, Waren, Germany.
- Gynecology, Operative and Conservative Senology, Faculty of Medicine, University of Augsburg and CCC WERA, Augsburg, Germany; Bavarian Cancer Research Center (BZKF), Study Group Breast Cancer, Erlangen, Germany.
- Department of Gynecology and Obstetrics, University Hospital Aachen, Aachen, Germany.
- Department of Surgery, Breast Center, Capio St. Göran's Hospital, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Förderung
- Merit Medical Systems
Zitieren
APA
Hartmann, S., Banys-Paluchowski, M., Berger, T., Ditsch, N., Stickeler, E., de Boniface, J., Gentilini, O. D., Schroth, J., Karadeniz Cakmak, G., Rubio, I. T., Gasparri, M. L., Kontos, M., Bonci, E. A., Niinikoski, L., Murawa, D., Kadayaprath, G., Pinto, D., Peintinger, F., Schlichting, E., …, & AXSANA Study Group (2025). Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655). European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110253
Vancouver
Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, et al. Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655). European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110253
BibTeX
@article{Hartmann2025,
author = {Hartmann, Steffi and Banys-Paluchowski, Maggie and Berger, Tomasz and Ditsch, Nina and Stickeler, Elmar and de Boniface, Jana and Gentilini, Oreste Davide and Schroth, Jennifer and Karadeniz Cakmak, Guldeniz and Rubio, Isabel T and Gasparri, Maria Luisa and Kontos, Michalis and Bonci, Eduard-Alexandru and Niinikoski, Laura and Murawa, Dawid and Kadayaprath, Geeta and Pinto, David and Peintinger, Florentia and Schlichting, Ellen and Dostalek, Lukas and Nina, Helidon and Valiyeva, Hagigat and Vanhoeij, Marian and Perhavec, Andraž and Zippel, Douglas and Rebaza, Lia Pamela and Thongvitokomarn, Sarun and Fröhlich, Sarah and Ruf, Franziska and Rief, Angelika and Wihlfahrt, Kristina and Basali, Timo and Thill, Marc and Lux, Michael Patrick and Loibl, Sibylle and Kolberg, Hans-Christian and Blohmer, Jens-Uwe and Hahn, Markus and Gurleyik, Meryem Gunay and Porpiglia, Mauro and Gunay, Semra and Zetterlund, Linda and Kuehn, Thorsten and AXSANA Study Group, AXSANA Study Group},
title = {Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2025.110253}
}
EUVIMED